Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.

ABSTRACT: Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid biopsies can be utilized to overcome the inherent limitations of tissue sampling and identify the most appropriate biomarker-informed treatment option for patients. The Blood First Assay Screening Trial is a global, open-label, multicohort trial that evaluates the efficacy and safety of multiple therapies in patients with advanced/metastatic NSCLC and targetable alterations identified by liquid biopsy. We present data from Cohort D (ROS1-positive). Patients ≥18 years of age with stage IIIB/IV, ROS1-positive NSCLC detected by liquid biopsies received ent

SUBMITTER: Peters S 

PROVIDER: S-EPMC11271410 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature